The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma

Cell Death Discovery

Volumn 1, Issue 1, 2015, Pages

  Lakoma, A ^a   Barbieri, E ^b   Agarwal, S ^b   Jackson, J ^c   Chen, Z ^b   Kim, Y ^c   McVay, M ^a   Shohet, J M ^b   Kim, E S ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84976413318     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2015.26     Document Type: Article

References (35)

1. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011; 47: 561–571.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202–2211.
3. Laverdière C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 1131–1140.
4. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007; 120: e1229–e1236.
5. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993; 53: 5269–5273.
6. Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C et al. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007; 6: 2685–2696.
7. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–299.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299–303.
9. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.
10. Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF et al. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets 2010; 10: 319–331.
11. Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 2011; 102: 605–613.
12. Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia 2011; 25: 856–867.
13. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012; 11: 4579–4588.
14. Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS ONE 2013; 8: e72281.
15. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R et al. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013; 60: 633–641.
16. Van Maerken T, Rihani A, Van Goethem A, De Paepe A, Speleman F, Vandesompele J. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer. Cancer Lett 2014; 344: 157–165.
17. Ray-Coquard I, Blay J-Y, Italiano A, Le Cesne A, Penel N, Zhi J et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13: 1133–1140.
18. Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog 2013; 52: 39–48.
19. Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC et al. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer 2011; 10: 49.
20. Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 2011; 14: 255–266.
21. Popowicz GM, Dömling A, Holak TA. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl 2011; 50: 2680–2688.
22. Vu BT, Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol 2011; 348: 151–172.
23. Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett 2013; 4: 466–469.
24. Ding Q, Zhang Z, Liu J-J, Jiang N, Zhang J, Ross TM et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013; 56: 5979–5983.
25. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358–2365.
26. Chen L, Tweddle DA. p53, SKP2, and DKK3 as MYCN target genes and their potential therapeutic significance. Front Oncol 2012; 2: 173.
27. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015; 66: 49–63.
28. Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013; 73: 2587–2597.
29. Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res 2014; 20: 3742–3752.
30. Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 2014; 14: 255–266.
31. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 2010; 9: 2545–2557.
32. Lau LMS, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997–1003.
33. Michaelis M, Rothweiler F, Klassert D, Deimling von A, Weber K, Fehse B et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69: 416–421.
34. Hsu DM, Agarwal S, Benham A, Coarfa C, Trahan DN, Chen Z et al. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 2013; 73: 4134–4146.
35. Patterson DM, Shohet JM, Kim ES. Preclinical Models of Pediatric Solid Tumors (Neuroblastoma) and Their Use in Drug Discovery. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2001.